Skip to main content
Clinical Trials/EUCTR2020-003321-32-DK
EUCTR2020-003321-32-DK
Active, not recruiting
Phase 1

Evaluation of intra articular Tranexamic acid for reduction of total blood loss in total hip arthroplasty

Hvidovre Hospital, Dep. of Orthopaedic Surgery0 sites100 target enrollmentJuly 7, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
The benefit of additional Tranexamic Acid (TXA) injected intra-articularat the end of surgery for patients undergoing a unilateral total hiparthroplasty in addition to conventional IV TXA to reduce the bleeding.
Sponsor
Hvidovre Hospital, Dep. of Orthopaedic Surgery
Enrollment
100
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 7, 2020
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Hvidovre Hospital, Dep. of Orthopaedic Surgery

Eligibility Criteria

Inclusion Criteria

  • \= 18 years
  • Undergoing surgery for unilateral total hip arthroplasty
  • Able to give ones consent either verbally or written.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 40
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 60

Exclusion Criteria

  • \- Operation performed in general anaesthesia
  • \- Allergi to TXA
  • \- In treatment with the following anticoagulatia: ADP receptorinhibitors, vitamin\-K antagonist(within 5\-7 days before the operation). Factor Xa inhibitors, thrombine\-inhibitors
  • \- Use of oral anticonceptiva
  • \- Kown with thrombophilia
  • \- Reduced kidney function (GFR \<60 ml/hour)
  • \- Participated in a clinical trial within the last 30 days
  • \- Alcoholism and morphinism
  • \- Females: menstruation within the last 12 months
  • \- Patients who are not able to speak and understand Danish

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Does tranexamic acid, a medicine used in treating and preventing bleeding problems, reduce the blood loss when it is injected directly into the knee joint after a total knee prosthesisThe benefit of additional Tranexamic Acid (TXA) injected intra-articular at the end of surgery for patients undergoing a unilateral total knee arthroplasty in addition to conventional IV TXA to reduce the bleeding.MedDRA version: 14.1Level: LLTClassification code 10003398Term: Arthroplasty of kneeSystem Organ Class: 100000004865Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
EUCTR2013-003169-33-DKAnders Troelsen
Unknown
Phase 4
The Efficacy of Intra-articular Tranexamic acid combined with Epinephrine in Arthroscopic ACL reconstruction: Double-blinded randomized controlled trialACL injury patientACL injuryTranexamic acid
TCTR20211124002akornping Hospital124
Completed
Phase 3
Assessment of effect of Tranexamic acid on hemorrhage reduction in hysterectomyCondition 1: Hysterectomy. Condition 2: Blood transfusion. Condition 3: Tranexamic acid.Acquired absence of both cervix and uterusZ90.710
IRCT20210703051769N1Esfahan University of Medical Sciences60
Completed
Not Applicable
Tranexamic Acid and its effect on TURP operatiobenign hypertrophy of prostate.Hypertrophy (benign) of prostate
IRCT2015030111822N5Vice chancellor for Research and Technology, Hamadan University of Medical Science70
Recruiting
Not Applicable
Efficacy of intravenous tranexamic acid administration for open wedge distal tuberosity osteotomy (OWDTO):a randomized control trial
JPRN-UMIN000034842Hyogo College of Medicine60